UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2014-03, Vol.370 (11), p.997-1007

2014

Volltextzugriff (PDF)

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2014-03, Vol.370 (11), p.997-1007

2014

Volltextzugriff (PDF)

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

The New England journal of medicine, 2014-03, Vol.370 (11), p.1008-1018

2014

Volltextzugriff (PDF)

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Blood, 2015-12, Vol.126 (25), p.2686-2694

2015

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for Immunotherapy of Cancer, 2017-06, Vol.5 (1), p.50-50, Article 50

2017

Volltextzugriff (PDF)

High‐Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer

The oncologist (Dayton, Ohio), 2000-02, Vol.5 (1), p.1-13

2000

Volltextzugriff (PDF)

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

The Lancet (British edition), 2011-03, Vol.377 (9768), p.813-822

2011

Volltextzugriff (PDF)

Nonablative allogeneic hematopoietic stem cell transplantation

Current opinion in oncology, 2001-01, Vol.13 (1), p.27-32

2001

Volltextzugriff (PDF)

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

The lancet oncology, 2010-03, Vol.11 (3), p.275-280

2010

Volltextzugriff (PDF)

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?

Seminars in oncology, 2001-08, Vol.28 (4), p.377-388

2001

Volltextzugriff (PDF)

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

JOURNAL OF CLINICAL ONCOLOGY, 2013, Vol.31 (15_suppl), p.TPS8617-TPS8617

2013

Volltextzugriff (PDF)

Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7003-7003

2013

Volltextzugriff (PDF)

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS8618-TPS8618

2013

Volltextzugriff (PDF)

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7005-7005

2013

Volltextzugriff (PDF)

A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)

JOURNAL OF CLINICAL ONCOLOGY, 2013, Vol.31 (15_suppl), p.TPS7131-TPS7131

2013

Volltextzugriff (PDF)

Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4510-4510

2012

Volltextzugriff (PDF)

Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8526-8526

2013

Volltextzugriff (PDF)

Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8501-8501

2013

Volltextzugriff (PDF)

Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8500-8500

2013

Volltextzugriff (PDF)

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8519-8519

2013

Volltextzugriff (PDF)

Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7017-7017

2013

Volltextzugriff (PDF)

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS7133-TPS7133

2013

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for immunotherapy of cancer, 2017, Vol.5, p.50

2017

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(42)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(20)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Female
(14)
Middle Aged
(12)
Male
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Adult
(9)
Oncology
(9)
Aged
(8)
Denosumab
(7)
Hematopoietic Stem Cell Transplantation
(7)
Aged, 80 And Over
(5)
Breast Neoplasms - Drug Therapy
(5)
Breast Neoplasms - Pathology
(5)
Breast Neoplasms - Therapy
(5)
Double-Blind Method
(5)
Pharmacology. Drug Treatments
(5)
Antibodies, Monoclonal, Humanized
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

High‐Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

Nonablative allogeneic hematopoietic stem cell transplantation

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics

Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)

Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL)

Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)

Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

Suchergebnisse filtern